The changing of natural history of nonalcoholic fatty liver disease (NAFLD): is advanced fibrosis the best predictor of long-term adverse outcomes?

Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease observed in clinical practice both in developed and in developing Countries (1). NAFLD affects approximately 25–35% among general adult population, 70–75% among patients with type 2 diabetes (T2DM) and up to 95% among those with obesity (1).